We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
MiniMed Launches MiniMed Flex Pump in Europe to Expand Diabetes Care
Read MoreHide Full Article
Key Takeaways
MED is positioning Trilivy alongside GLP-1 drugs, emphasizing nutrition, coaching and metabolic health.
MED coach productivity reached 54% in Q3, improving for the fourth consecutive quarter year over year.
MED's Reset 5 & 1 plan reduced visceral fat 14% while preserving 98% of lean mass over 16 weeks.
MiniMed (MMED - Free Report) has launched commercial shipments of its MiniMed Flex system across Europe following an initial customer experience phase in select markets. The new insulin pump expands the company's automated insulin delivery portfolio with a more compact design aimed at making diabetes management more convenient and discreet.
The launch strengthens MMED's competitive positioning in the growing diabetes technology market by expanding its product offerings and addressing patient demand for more convenient insulin delivery solutions. Leveraging its established SmartGuard technology in a new form factor could support broader adoption and improve the company's ability to compete in the automated insulin delivery market. Wider European availability over the coming months is expected to provide an additional growth opportunity.
MMED Stock Trend
Year to date, the stock lost 3.8%, underperforming the industry’s 8.9% growth and the S&P 500’s 7.2% gain.
The launch of MiniMed Flex is likely to support MMED's long-term growth by strengthening its position in the automated insulin delivery market and expanding its addressable patient base. Its compact design and app-based control could improve patient convenience and encourage greater adoption among individuals seeking more discreet diabetes management solutions.
Moreover, leveraging the established SmartGuard algorithm in a new product platform allows MMED to build on its existing technology while differentiating its portfolio. Gradual expansion across European markets and planned compatibility with additional glucose sensors could further improve the product's appeal and support recurring revenue growth over time.
MMED currently has a market capitalization of $5.25 billion.
Image Source: Zacks Investment Research
More on the News
MiniMed Flex is approximately half the size of previous MiniMed pumps and holds up to 300 units of insulin. The system features a screenless design, with primary functions managed through a compatible iOS or Android application. It is also rechargeable and supports wireless software updates, which could allow users to access future product improvements.
The pump is designed to work with MiniMed's Extended infusion set, which can be worn for up to seven days and delivers up to 96% fewer injections compared with traditional insulin therapy. The platform is initially rolling out in Europe with the Simplera Sync sensor, which offers up to seven days of wear and a two-step insertion process. Compatibility with Abbott's Instinct sensor, which offers up to 15 days of wear, is planned for 2027.
The system uses the SmartGuard algorithm, which automatically adjusts insulin delivery every five minutes based on real-time glucose readings from a compatible continuous glucose monitor. Its Meal Detection technology can identify rapid increases in sensor glucose and deliver automatic correction doses when meal boluses are occasionally missed, or carbohydrate intake is underestimated.
However, MiniMed Flex remains an advanced hybrid closed-loop system and requires users to announce meals and administer meal boluses. MiniMed highlighted the established clinical performance of the MiniMed 780G system, which uses the same algorithm. Real-world findings showed 80% time in range among users with recommended optimal settings, while another study demonstrated more than 90% overnight time in range.
Additionally, nine out of 10 users with optimal settings achieved the international target of more than 70% time in range. The system is CE-marked in Europe for individuals aged two years and older with insulin-treated type 1 and type 2 diabetes, as well as for use during pregnancy. MiniMed Flex is also waterproof up to 2.4 meters for 1 hour and 45 minutes.
The company noted that a next-generation algorithm is also in development and is expected to be accessible through future wireless software updates, although it has not yet received regulatory approval or become commercially available. MiniMed Flex is therefore building on the existing clinical capabilities of the 780G platform while providing a pathway for future technology enhancements.
Industry Prospects Favoring the Market
Per a report by Data Bridge Market Research, the global automated insulin delivery devices market size was valued at $3.29 billion in 2024 and is projected to reach $7.83 billion by 2032, at a CAGR of 11.43%.
The global automated insulin delivery devices market is experiencing significant growth, driven by the rising prevalence of diabetes and advancements in technology.
Other News
Recently, MMED announced that the FDA has cleared MiniMed Fit, its first tubeless insulin pump, expanding its automated insulin delivery portfolio in the United States. The system offers up to seven days of wear, a 300-unit insulin capacity, app-based control and the company's SmartGuard technology. With up to twice the wear time and 50% more insulin capacity than other tubeless options, MiniMed Fit is designed to reduce pump changes and simplify diabetes management.
MMED’s Zacks Rank & Key Picks
Currently, MMED carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are OPKO Health (OPK - Free Report) , Globus Medical (GMED - Free Report) and Merit Medical Systems (MMSI - Free Report) .
OPKO Health, currently carrying a Zacks Rank #2 (Buy), reported a second-quarter 2026 adjusted loss of 1 cent per share, which surpassed the Zacks Consensus Estimate by 87.5%. Revenues of $163.6 million beat the Zacks Consensus Estimate by 24.7%. You can see the complete list of today’s Zacks #1 Rank stocks here.
OPK has an estimated earnings growth rate of 23.3% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 95.1%.
Globus Medical, currently carrying a Zacks Rank #2, reported a second-quarter 2026 adjusted earnings per share (EPS) of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.
Merit Medical Systems, carrying a Zacks Rank #2 at present, reported second-quarter 2026 adjusted EPS of $1.19, which beat the Zacks Consensus Estimate by 23.9%. Revenues of $418.8 million surpassed the Zacks Consensus Estimate by 3.5%.
MMSI has an estimated long-term earnings growth rate of 10.4%. Merit Medical Systems’ earnings surpassed estimates in the trailing four quarters, with the average surprise being 14.1%.
Image: Bigstock
MiniMed Launches MiniMed Flex Pump in Europe to Expand Diabetes Care
Key Takeaways
MiniMed (MMED - Free Report) has launched commercial shipments of its MiniMed Flex system across Europe following an initial customer experience phase in select markets. The new insulin pump expands the company's automated insulin delivery portfolio with a more compact design aimed at making diabetes management more convenient and discreet.
The launch strengthens MMED's competitive positioning in the growing diabetes technology market by expanding its product offerings and addressing patient demand for more convenient insulin delivery solutions. Leveraging its established SmartGuard technology in a new form factor could support broader adoption and improve the company's ability to compete in the automated insulin delivery market. Wider European availability over the coming months is expected to provide an additional growth opportunity.
MMED Stock Trend
Year to date, the stock lost 3.8%, underperforming the industry’s 8.9% growth and the S&P 500’s 7.2% gain.
The launch of MiniMed Flex is likely to support MMED's long-term growth by strengthening its position in the automated insulin delivery market and expanding its addressable patient base. Its compact design and app-based control could improve patient convenience and encourage greater adoption among individuals seeking more discreet diabetes management solutions.
Moreover, leveraging the established SmartGuard algorithm in a new product platform allows MMED to build on its existing technology while differentiating its portfolio. Gradual expansion across European markets and planned compatibility with additional glucose sensors could further improve the product's appeal and support recurring revenue growth over time.
MMED currently has a market capitalization of $5.25 billion.
Image Source: Zacks Investment Research
More on the News
MiniMed Flex is approximately half the size of previous MiniMed pumps and holds up to 300 units of insulin. The system features a screenless design, with primary functions managed through a compatible iOS or Android application. It is also rechargeable and supports wireless software updates, which could allow users to access future product improvements.
The pump is designed to work with MiniMed's Extended infusion set, which can be worn for up to seven days and delivers up to 96% fewer injections compared with traditional insulin therapy. The platform is initially rolling out in Europe with the Simplera Sync sensor, which offers up to seven days of wear and a two-step insertion process. Compatibility with Abbott's Instinct sensor, which offers up to 15 days of wear, is planned for 2027.
The system uses the SmartGuard algorithm, which automatically adjusts insulin delivery every five minutes based on real-time glucose readings from a compatible continuous glucose monitor. Its Meal Detection technology can identify rapid increases in sensor glucose and deliver automatic correction doses when meal boluses are occasionally missed, or carbohydrate intake is underestimated.
However, MiniMed Flex remains an advanced hybrid closed-loop system and requires users to announce meals and administer meal boluses. MiniMed highlighted the established clinical performance of the MiniMed 780G system, which uses the same algorithm. Real-world findings showed 80% time in range among users with recommended optimal settings, while another study demonstrated more than 90% overnight time in range.
Additionally, nine out of 10 users with optimal settings achieved the international target of more than 70% time in range. The system is CE-marked in Europe for individuals aged two years and older with insulin-treated type 1 and type 2 diabetes, as well as for use during pregnancy. MiniMed Flex is also waterproof up to 2.4 meters for 1 hour and 45 minutes.
The company noted that a next-generation algorithm is also in development and is expected to be accessible through future wireless software updates, although it has not yet received regulatory approval or become commercially available. MiniMed Flex is therefore building on the existing clinical capabilities of the 780G platform while providing a pathway for future technology enhancements.
Industry Prospects Favoring the Market
Per a report by Data Bridge Market Research, the global automated insulin delivery devices market size was valued at $3.29 billion in 2024 and is projected to reach $7.83 billion by 2032, at a CAGR of 11.43%.
The global automated insulin delivery devices market is experiencing significant growth, driven by the rising prevalence of diabetes and advancements in technology.
Other News
Recently, MMED announced that the FDA has cleared MiniMed Fit, its first tubeless insulin pump, expanding its automated insulin delivery portfolio in the United States. The system offers up to seven days of wear, a 300-unit insulin capacity, app-based control and the company's SmartGuard technology. With up to twice the wear time and 50% more insulin capacity than other tubeless options, MiniMed Fit is designed to reduce pump changes and simplify diabetes management.
MMED’s Zacks Rank & Key Picks
Currently, MMED carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are OPKO Health (OPK - Free Report) , Globus Medical (GMED - Free Report) and Merit Medical Systems (MMSI - Free Report) .
OPKO Health, currently carrying a Zacks Rank #2 (Buy), reported a second-quarter 2026 adjusted loss of 1 cent per share, which surpassed the Zacks Consensus Estimate by 87.5%. Revenues of $163.6 million beat the Zacks Consensus Estimate by 24.7%. You can see the complete list of today’s Zacks #1 Rank stocks here.
OPK has an estimated earnings growth rate of 23.3% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 95.1%.
Globus Medical, currently carrying a Zacks Rank #2, reported a second-quarter 2026 adjusted earnings per share (EPS) of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.
Merit Medical Systems, carrying a Zacks Rank #2 at present, reported second-quarter 2026 adjusted EPS of $1.19, which beat the Zacks Consensus Estimate by 23.9%. Revenues of $418.8 million surpassed the Zacks Consensus Estimate by 3.5%.
MMSI has an estimated long-term earnings growth rate of 10.4%. Merit Medical Systems’ earnings surpassed estimates in the trailing four quarters, with the average surprise being 14.1%.